$AVEO Crickets from IR on this: as October 4, 2018, AVEO reports mOS as follows: Tivozanib 16.4 (13.5, 21.6) Sorafenib 19.7 (15.0, ---). As of August 15, 2019, AVEO reports mOS as follows:16.4 months for tivozanib (95% CI: 13.4-22.2) and 19.7 months for sorafenib (95% CI: 15.0-24.2). It appears the new mOS figures reflect the maturing of the 338 participants included in the October 2018 class. The problem is that with 350 patients accounted for in the new corporate presentation, 12 new participants, previously unlocated, have been located. Their deaths are included in the updated HR of 0.99. But it is not clear to me their deaths are included in the updated mOS numbers. If they are, it would seem of the 9 Sorafenib participants previously lost to follow-up, 4 died before 19.7 months, four died after 19.7 months, and one died exactly at 19.7 months?
  • 23